Feasibility of Preoperative Chemotherapy with Docetaxel, Cisplatin, and 5-Fluorouracil versus Adriamycin, Cisplatin, and 5-Fluorouracil for Resectable Advanced Esophageal Cancer

Publisher： Karger

E-ISSN： 1423-0232|92|2|101-108

ISSN： 0030-2414

Source： Oncology, Vol.92, Iss.2, 2016-12, pp. : 101-108

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Prospective Phase II Study of Neoadjuvant Therapy with Cisplatin, 5-Fluorouracil, and Bevacizumab for Locally Advanced Resectable Esophageal Cancer

By  

Oncology Research and Treatment, Vol. 35, Iss. 7-8, 2012-07 ,pp. : 427-431

Karger

Access to resources Recommend Favorite

DCF versus CF for esophagus cancer

By  

DISEASES OF THE ESOPHAGUS (ELECTRONIC), Vol. 28, Iss. 2, 2015-02 ,pp. : 180-187

John Wiley & Sons Inc

Access to resources Recommend Favorite

Feasibility and safety of hyperthermic intraperitoneal chemotherapy using 5‐fluorouracil combined with cisplatin and mitomycin C in patients undergoing gastrectomy for advanced gastric cancer

By  

JOURNAL OF SURGICAL ONCOLOGY, Vol. 116, Iss. 8, 2017-12 ,pp. : 1159-1165

John Wiley & Sons Inc

Access to resources Recommend Favorite

Prognostic Advantage of Docetaxel/Cisplatin/ 5-Fluorouracil Neoadjuvant Chemotherapy in Clinical Stage II/III Esophageal Squamous Cell Carcinoma due to Excellent Control of Preoperative Disease and Postoperative Lymph Node Recurrence

By  

Oncology, Vol. 92, Iss. 4, 2017-01 ,pp. : 221-228

Karger

Access to resources Recommend Favorite

Prognostic Factors in Patients Receiving Neoadjuvant 5-Fluorouracil plus Cisplatin for Advanced Esophageal Cancer (JCOG9907)

By  

Oncology, Vol. 89, Iss. 3, 2015-04 ,pp. : 143-151

Karger

Access to resources Recommend Favorite